Q1 2025 · 13F-HR
BRAIDWELL LPholdings as filed
Filed 2025-05-15 · accession 0001420506-25-001293
$2.84B
Reported value
64
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 40131MAD1 | GH 1.25 02/15/31 | GUARDANT HEALTH INC | $227.4M | 7.99% | 219,454,000 | Common | SOLE |
| 67011XAB9 | NVCR 0 11/01/25 | NOVOCURE LTD | $136.6M | 4.80% | 140,834,000 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $131.8M | 4.63% | 1,191,925 | Common | SOLE |
| 52490G102 | LEGN | LEGEND BIOTECH CORP | $101.0M | 3.55% | 2,977,951 | Common | SOLE |
| 759916AD1 | RGEN 1 12/15/28 | REPLIGEN CORP | $95.8M | 3.37% | 98,000,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $95.2M | 3.35% | 160,849 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $90.9M | 3.20% | 2,709,875 | Common | SOLE |
| 450056AB2 | IRTC 1.5 09/01/29 | IRHYTHM TECHNOLOGIES INC | $89.7M | 3.15% | 86,000,000 | Common | SOLE |
| 64049MAB6 | NEO 0.25 01/15/28 | NEOGENOMICS INC | $87.9M | 3.09% | 101,381,000 | Common | SOLE |
| 016255101 | ALGN | ALIGN TECHNOLOGY INC | $84.3M | 2.96% | 530,530 | Common | SOLE |
| 46333XAH1 | IRWD 1.5 06/15/26 | IRONWOOD PHARMACEUTICALS INC | $82.5M | 2.90% | 92,740,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $80.4M | 2.83% | 3,283,317 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $72.3M | 2.54% | 400,744 | Common | SOLE |
| 10806XAB8 | BBIO 2.5 03/15/27 | BRIDGEBIO PHARMA INC | $72.0M | 2.53% | 62,838,000 | Common | SOLE |
| 883556102 | TMO | THERMO FISHER SCIENTIFIC INC | $63.6M | 2.23% | 127,733 | Common | SOLE |
| 235851102 | DHR | DANAHER CORPORATION | $63.4M | 2.23% | 309,339 | Common | SOLE |
| 377322102 | GKOS | GLAUKOS CORP | $61.5M | 2.16% | 624,435 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $59.6M | 2.10% | 840,945 | Common | SOLE |
| 450056106 | IRTC | IRHYTHM TECHNOLOGIES INC | $58.2M | 2.05% | 556,391 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $57.5M | 2.02% | 1,540,362 | Common | SOLE |
| 89377M109 | TMDX | TRANSMEDICS GROUP INC | $57.5M | 2.02% | 854,884 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $56.5M | 1.99% | 1,327,327 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $54.1M | 1.90% | 2,458,808 | Common | SOLE |
| 457730109 | INSP | INSPIRE MED SYS INC | $48.2M | 1.69% | 302,410 | Common | SOLE |
| 10806XAD4 | BBIO 2.25 02/01/29 | BRIDGEBIO PHARMA INC | $43.8M | 1.54% | 48,594,000 | Common | SOLE |
| 45258DAB1 | IMCR 2.5 02/01/30 | IMMUNOCORE HLDGS PLC | $43.8M | 1.54% | 51,828,000 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $43.6M | 1.53% | 1,962,909 | Common | SOLE |
| 46120E602 | ISRG | INTUITIVE SURGICAL INC | $43.6M | 1.53% | 88,000 | Common | SOLE |
| 02081G201 | ATEC | ALPHATEC HLDGS INC | $43.2M | 1.52% | 4,259,429 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $41.6M | 1.46% | 2,578,404 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $38.9M | 1.37% | 439,968 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $37.9M | 1.33% | 3,621,344 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $36.1M | 1.27% | 1,652,334 | Common | SOLE |
| 00650F109 | ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $35.7M | 1.25% | 4,803,794 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $34.7M | 1.22% | 1,435,955 | Common | SOLE |
| 70975L107 | PEN | PENUMBRA INC | $29.4M | 1.04% | 110,128 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $28.2M | 0.99% | 2,162,803 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $28.0M | 0.99% | 3,536,853 | Common | SOLE |
| 68752L100 | KIDS | ORTHOPEDIATRICS CORP | $27.3M | 0.96% | 1,107,770 | Common | SOLE |
| 415858109 | HROW | HARROW INC | $25.5M | 0.89% | 956,839 | Common | SOLE |
| 252131AM9 | DXCM 0.375 05/15/28 | DEXCOM INC | $22.8M | 0.80% | 25,450,000 | Common | SOLE |
| 56600D107 | MRVI | MARAVAI LIFESCIENCES HLDGS I | $18.5M | 0.65% | 8,353,287 | Common | SOLE |
| 252131AK3 | DXCM 0.25 11/15/25 | DEXCOM INC | $18.0M | 0.63% | 18,500,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $17.6M | 0.62% | 1,655,690 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $16.6M | 0.58% | 106,713 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $16.1M | 0.57% | 1,572,426 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $16.1M | 0.57% | 48,690 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $15.0M | 0.53% | 234,500 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $14.3M | 0.50% | 1,461,826 | Common | SOLE |
| 759916109 | RGEN | REPLIGEN CORP | $10.4M | 0.37% | 81,656 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $9.7M | 0.34% | 6,622,584 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $8.9M | 0.31% | 884,306 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $7.4M | 0.26% | 980,773 | Common | SOLE |
| 14843C105 | CSTL | CASTLE BIOSCIENCES INC | $7.3M | 0.26% | 365,247 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $6.8M | 0.24% | 375,355 | Common | SOLE |
| 02081GAB8 | ATEC 0.75 08/01/26 | ALPHATEC HLDGS INC | $5.8M | 0.20% | 5,818,000 | Common | SOLE |
| 745848101 | LUNG | PULMONX CORP | $5.1M | 0.18% | 752,541 | Common | SOLE |
| 59267L107 | — | METSERA INC | $4.8M | 0.17% | 175,000 | Common | SOLE |
| 002942100 | AARD | AARDVARK THERAPEUTICS INC | $3.8M | 0.13% | 500,000 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $3.6M | 0.13% | 1,440,499 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $3.2M | 0.11% | 2,472,806 | Common | SOLE |
| 08659B102 | BBNX | BETA BIONICS INC | $1.7M | 0.06% | 140,000 | Common | SOLE |
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $1.3M | 0.05% | 825,732 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $453,402 | 0.02% | 72,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.